Biochemical markers of bone metabolism in multiple myeloma (Q36471234)

14 August 2017

1 reference

title

Biochemical markers of bone metabolism in multiple myeloma (English)

1 reference

14 August 2017

Evangelos Terpos

1

1 reference

14 August 2017

1 January 2006

1 reference

14 August 2017

Cancer Treatment Reviews

1 reference

14 August 2017

32 Suppl 1

1 reference

14 August 2017

15-19

1 reference

Bisphosphonates: clinical experience

14 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2806%2980004-6

7 January 2021

https://api.crossref.org/works/10.1016%2FS0305-7372%2806%2980004-6

1 reference

7 January 2021

Bone resorption parameters [carboxy-terminal telopeptide of type-I collagen (ICTP), amino-terminal collagen type-I telopeptide (NTx), and deoxypyridinoline (Dpd)] in MGUS and multiple myeloma.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2806%2980004-6

7 January 2021

The role of markers of bone remodeling in multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2806%2980004-6

7 January 2021

Serum tartrate-resistant acid phosphatase 5b, but not 5a, correlates with other markers of bone turnover and bone mineral density.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2806%2980004-6

7 January 2021

Tartrate-resistant acid phosphatase 5b: a novel serum marker of bone resorption

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2806%2980004-6

7 January 2021

Monitoring of multiple myeloma patients by simultaneously measuring marker substances of bone resorption and formation

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2806%2980004-6

7 January 2021

Evaluation of bone disease in multiple myeloma: a comparison between the resorption markers urinary deoxypyridinoline/creatinine (DPD) and serum ICTP, and an evaluation of the DPD/osteocalcin and ICTP/osteocalcin ratios

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2806%2980004-6

7 January 2021

Prognostic value of serum markers of bone metabolism in untreated multiple myeloma patients

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2806%2980004-6

7 January 2021

Soluble receptor activator of nuclear factor kappaB ligand-osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic index

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2806%2980004-6

7 January 2021

Serum markers of bone metabolism in multiple myeloma: prognostic value of the carboxy-terminal telopeptide of type I collagen (ICTP)

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2806%2980004-6

7 January 2021

Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2806%2980004-6

7 January 2021

Serum osteoprotegerin levels are reduced in patients with multiple myeloma with lytic bone disease

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2806%2980004-6

7 January 2021

Response to bortezomib is associated to osteoblastic activation in patients with multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2806%2980004-6

7 January 2021

Autologous stem cell transplantation normalizes abnormal bone remodeling and sRANKL/osteoprotegerin ratio in patients with multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2806%2980004-6

7 January 2021

Comparison of five biochemical markers of bone resorption in multiple myeloma: elevated pre-treatment levels of S-ICTP and U-Ntx are predictive for early progression of the bone disease during standard chemotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2806%2980004-6

7 January 2021

Evaluation of bone disease in multiple myeloma: a correlation between biochemical markers of bone metabolism and other clinical parameters in untreated multiple myeloma patients

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2806%2980004-6

7 January 2021

Serum concentration of the cross-linked carboxyterminal telopeptide of type I collagen (ICTP) is a useful prognostic indicator in multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2806%2980004-6

7 January 2021

Monitoring the action of clodronate with type I collagen metabolites in multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2806%2980004-6

7 January 2021

Novel Serum Markers of Bone Resorption: Clinical Assessment and Comparison with Established Urinary Indices

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2806%2980004-6

7 January 2021

Biochemical markers of bone metabolism reflect osteoclastic and osteoblastic activity in multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2806%2980004-6

7 January 2021

Comparison of urinary markers for bone resorption in multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2806%2980004-6

7 January 2021

Tartrate-resistant acid phosphatase isoform 5b: a novel serum marker for monitoring bone disease in multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2806%2980004-6

7 January 2021

Role of receptor activator of nuclear factor-kappa B ligand (RANKL), osteoprotegerin and macrophage protein 1-alpha (MIP-1a) in monoclonal gammopathy of undetermined significance (MGUS)

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2806%2980004-6

7 January 2021

Serum bone sialoprotein as a marker of tumour burden and neoplastic bone involvement and as a prognostic factor in multiple myeloma.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2806%2980004-6

7 January 2021

Pamidronate is superior to ibandronate in decreasing bone resorption, interleukin-6 and beta 2-microglobulin in multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2806%2980004-6

7 January 2021

Effect of pamidronate administration on markers of bone turnover and disease activity in multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2806%2980004-6

7 January 2021

Pamidronate increases markers of bone formation in patients with multiple myeloma in plateau phase under interferon-alpha treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2806%2980004-6

7 January 2021

The combination of intermediate doses of thalidomide with dexamethasone is an effective treatment for patients with refractory/relapsed multiple myeloma and normalizes abnormal bone remodeling, through the reduction of sRANKL/osteoprotegerin ratio

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2806%2980004-6

7 January 2021

High serum bone-specific alkaline phosphatase level after bortezomib-combined therapy in refractory multiple myeloma: possible role of bortezomib on osteoblast differentiation

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2806%2980004-6

7 January 2021

A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2806%2980004-6

7 January 2021

The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2806%2980004-6

7 January 2021

Myeloma cells suppress bone formation by secreting a soluble Wnt inhibitor, sFRP-2.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2806%2980004-6

7 January 2021

10.1016/S0305-7372(06)80004-6

Identifiers

DOI

1 reference

14 August 2017

1 reference

PubMed ID

16680833